I have published extensively in reputable peer reviewed scientific journals, mainly in the field of psychopharmacology. My major reviews have covered various aspects of serotonin toxicity and neuroleptic malignant syndrome and the pharmacology of TCAs and MAOIs. My profile on 'Google Scholar' shows current citation counts and ‘H-index’.


The menu on the left links to PDF files, if available.

Recent Significant Papers

“Much ado about nothing”: Monoamine oxidase inhibitors, drug interactions and dietary tyramine. (2016). Gillman, P. K.
CNS spectrums. Editorial [2/1/2017] http://dx.doi.org/10.1017/S1092852916000651

Patient Safety and Methylene Blue-Associated Severe Serotonin Toxicity. (2016). Rosenbaum, H. and P. K. Gillman
A&A Case Reports 7(1): http://journals.lww.com/aacr/Citation/2016/07010/Patient_Safety_and_Methylene_Blue_Associated.07011.aspx.

Monoamine Oxidase Inhibitors: a Review Concerning Dietary Tyramine and Drug Interactions. (2017). Gillman, P. K. PsychoTropical Commentaries 17(1): 1-104.


Clomipramine: Potent SNRI Anti-Depressant. (2015). Gillman, P. K. PsychoTropical Commentaries 15(10): 1-4.


Delayed Recovery from General Anaesthesia: A Post-operative Diagnostic Dilemma and Implications of ICU Management of Serotonin Toxicity. Case report: Comment. (2015). Gillman, P. K. PsychoTropical Commentaries 15(12): 1-4.



Electroconvulsive Therapy (ECT). For Whom? (2015). Gillman, P. K. PsychoTropical Commentaries 15(10): 1-5.



Monoamine oxidase inhibitors, dietary tyramine and drug interactions. (2015). Gillman, P. K. PsychoTropical Commentaries 10: 1 – 53.


NEI link- http://www.neiglobal.com/Default.aspx?tabid=85


QT Interval Assessment, Psychotropic Drugs and the Influence of Product Information. (2015). Gillman, P. K. PsychoTropical Commentaries 15(5): 1-6.



Fatal methylene blue associated serotonin toxicity. (2014). Top, W. M., P. K. Gillman, C. J. de Langen and A. Kooy Neth J Med 72(3): 179-181.



Metaxalone (Skelaxin) and Serotonin Toxicity (Serotonin Syndrome): Warning of Potential for Fatalities if Combined with Serotonin Re-uptake Inhibitors. (2014). Gillman, P. K. PsychoTropical Commentaries 14(11): 1-5.



Regulatory Agencies (WHO, FDA) Offer Ill-Conceived Advice about Serotonin Toxicity (Serotonin Syndrome) with 5-HT3 antagonists: a Worldwide Problem. (2014). Gillman, P. K. PsychoTropical Commentaries 14(11): 1-6.



Atypical antipsychotics: where is the science, where is the evidence. (2013). Gillman, P. K. The Carlat Psychiatry Report 11(1): 3-5.



Atypical Anti-Psychotics and Humpty Dumpty. (2012). Gillman, P. K. PsychoTropical Commentaries 12(11): 1-12.



Methylene blue and serotonin reuptake inhibitors – an update. (2012). Gillman, P. K. Australian and New Zealand College of Anaesthetists Bulletin June: 43.


Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors. (2011). Gillman, P. K. Journal of Clinical Psychopharmacology 31(1): 66-74.



CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity. (2011). Gillman, P. K. Journal of Psychopharmacology 25(3): 429-423.



Finberg, J. and P. Gillman (2011). Pharmacology of MAO-B inhibitors and the cheese reaction. International Review of Neurobiology. M. Youdim and P. Riederer. Burlington, Elsevier Inc. Academic Press. 100: 169-190.


Combining antidepressants: Understanding Drug Interactions is the Sine Qua Non. (2010). Gillman, P. K. Advances in Psychiatric Treatment 16: 76-78.



Neuroleptic malignant syndrome: half a century of uncertainty suggests a Chimera. (2010). Gillman, P. K. Pharmacoepidemiology and Drug Safety 19(8): 876-877.



Neuroleptic Malignant Syndrome: Mechanisms, Interactions and Causality. (2010). Gillman, P. K. Movement Disorders 25(12): 1780-1790.



Is there sufficient evidence to suggest cyclobenzaprine might be implicated in causing serotonin toxicity? (2009). Gillman, P. K. American Journal of Emergency Medicine 27(4): 509-510.




Risk of severe serotonin toxicity following co-administration of methylene blue and serotonin reuptake inhibitors: an update on a case report of post-operative delirium. (2009). Stanford, S. C., B. J. Stanford and P. K. Gillman Journal of Psychopharmacology 24(10): 1433-1438.



Small doses of methylene blue, previously considered safe, can precipitate serotonin toxicity. (2009). Schwiebert, C., C. Irving and P. K. Gillman Anaesthesia 64: 924-924.




Triptans, Serotonin Agonists, and Serotonin Syndrome (Serotonin Toxicity): A Review. (2009). Gillman, P. K. Headache 50: 264-272.



Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. (2007). Ramsay, R. R., C. Dunford and P. K. Gillman Br J Pharmacol 152(6): 946-951.



Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. (2007). Gillman, P. K. British Journal of Pharmacology 151(6): 737-748.




Beware of anticholinergics in the elderly: delirious dangers of the deadly nightshade. (2006). Peterson, G., S. Jackson, M. Naunton and P. K. Gillman Journal of Pharmacy 25: 882-884.


Extracting value from case reports: lessons from serotonin toxicity. (2006). Gillman, P. K. Anaesthesia 61: 419-422.



Methylene Blue implicated in potentially fatal serotonin toxicity. (2006). Gillman, P. K. Anaesthesia 61: 1013-1014.



A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. (2006). Gillman, P. K. Biological Psychiatry 59(11): 1046-1051.



Serotonin Toxicity Associated with the Use of Linezolid: A Review of Postmarketing Data. (2006). Lawrence, K. R., M. Adra and P. K. Gillman Clinical Infectious Diseases 42: 1578-1583.



A systematic review of the serotonergic effects of mirtazapine: implications for its dual action status. (2006). Gillman, P. K. Human Psychopharmacology. Clinical and Experimental 21: 117-125.



Why most new antidepressants are ineffective: and how pharmaceutical companies have deceived doctors. (2006). Gillman, P. K. PsychoTropical Commentaries 6(4): 1-6.



Drug interactions and fluoxetine: a commentary from a clinician’s perspective. (2005). Gillman, P. K. Ex Op Drug Saf 4: 965-969.



Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. (2005). Gillman, P. K. British Journal of Anaesthesia 95: 434-441.



The serotonin syndrome. (2005). Gillman, P. K. New England Journal of Medicine 352(23): 2454-2456; author reply 2454-2456.



Understanding toxidromes: serotonin toxicity. A commentary on Montanes-Rada et al. (2005). Gillman, P. K. Journal of Clinical Psychopharmacology 25: 625-626.



Making sense of serotonin toxicity reports. A comment on Chopra et al. (2004). Gillman, P. K. World Journal of Biological Psychiatry 5: 166-167.



Moclobemide and the risk of serotonin toxicity (or serotonin syndrome). (2004). Gillman, P. K. Central Nervous System Drug Reviews 10: 83-85.



Gillman, P. K. and I. M. Whyte (2004). Serotonin syndrome. Adverse Syndromes and Psychiatric Drugs. P. Haddad, S. Dursun and B. Deakin. Oxford, Oxford University Press: 37-49.

The spectrum concept of serotonin toxicity. (2004). Gillman, P. K. Pain Medicine 5: 231-232.



Linezolid and serotonin toxicity. (2003). Gillman, P. K. Clinical Infectious Diseases 37: 1274-1275.



Commentary: clomipramine too soon after moclobemide. (1999). Gillman, P. K. Review of Psychiatry 4: 3-5.

The serotonin syndrome and its treatment. (1999). Gillman, P. K. Journal of Psychopharmacology 13(1): 100-109.



Serotonin syndrome following SSRI mono-therapy. (1998). Gillman, P. K. and S. Hodgens Human Psychopharmacology. Clinical and Experimental 13: 525-526.

Serotonin Syndrome: History and Risk. (1998). Gillman, P. K. Fundamental and Clinical Pharmacology 12(5): 482-491.



Serotonin syndrome treated with chlorpromazine. (1997). Gillman, P. K. Journal of Clinical Psychopharmacology 17: 128-129.



Serotonin syndrome: clomipramine too soon after moclobemide. (1997). Gillman, P. K. International Clinical Psychopharmacology 12: 339-342.



Successful treatment of serotonin syndrome with chlorpromazine. (1996). Gillman, P. K. Medical Journal of Australia 165: 345.

Possible serotonin syndrome with moclobemide and pethidine. (1995). Gillman, P. K. Medical Journal of Australia 162: 554.

Assessment of outcome after psychosurgery using the Present State Examination. (1983). Curson, D. A., T. Trauer, P. K. Bridges and P. K. Gillman British Journal of Psychiatry 143: 118-123.

Human platelet phenolsulphotransferase: separate control of the two forms and activity range in depressive illness. (1981). Carter, S. M., V. Glover, M. Sandler, P. K. Gillman and P. K. Bridges Clinica Chimica Acta 117(3): 333-344.

Indolic substances in plasma, cerebrospinal fluid, and frontal cortex of human subjects infused with saline or tryptophan. (1981). Gillman, P. K., J. R. Bartlett, P. K. Bridges, A. Hunt, A. J. Patel, B. D. Kantamaneni and G. Curzon Journal of Neurochemistry 37(2): 410-417.

Selecting patients for psychosurgery. (1981). Gillman, P. K., J. Bartlett and P. K. Bridges Biological Psychiatry 16: 1090-1094.

Relationships between tryptophan concentrations in human plasma, cerebrospinal fluid and cerebral cortex following tryptophan infusion. (1980). Gillman, P. K., J. R. Bartlett, P. K. Bridges, B. D. Kantamaneni and G. Curzon Neuropharmacology 19(12): 1241-1242.

Substances related to 5-hydroxytryptamine in plasma and in lumbar and ventricular fluids of psychiatric patients. (1980). Curzon, G., B. D. Kantamaneni, P. Van Boxel, P. K. Gillman, J. R. Bartlett and P. K. Bridges Acta Psychiatrica Scandinavica 280: 3-20.